Novo Nordisk invests $ 59 mn to expand insulin plant in Denmark

Novo Nordisk will invest 400 million Danish kroner (about $ 59 million) in a 500 square meter extension of the world’s largest insulin production plant in Kalundborg, Denmark.

Established in 1969, the Kalundborg production site today covers a total area of 1.1 million square metres. With its 3,400 employees, Kalundborg is a cornerstone of Novo Nordisk’s global production and produces 50 percent of the world’s insulin as well as a range of biopharmaceutical products. The extension is expected to be completed at the end of 2018.